Evidence map›Paper›PMID 28246356›Full record

ArticlemBio2017

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.

Charles D Morris, Parisa Azadnia, Natalia de Val, Nemil Vora, Andrew Honda, Erick Giang, Karen Saye-Francisco, Yushao Cheng, Xiaohe Lin, Colin J Mann and 7 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. A VScience advances · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Charles D MorrisDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Parisa AzadniaDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Natalia de ValDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Nemil VoraDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Andrew HondaDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Erick GiangDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Karen Saye-FranciscoDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Yushao ChengDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Xiaohe LinDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Colin J MannDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Jeffrey TangDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Devin SokDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Dennis R BurtonDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Mansun LawDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Linling HeDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA linling@scripps.edu jiang@scripps.edu.
Jiang ZhuDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA linling@scripps.edu jiang@scripps.edu.
Scripps Research Institute · USInternational AIDS Vaccine Initiative · USRagon Institute of MGH, MIT and Harvard · US

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CRISPIN, MAX · 2012 to 2018
$131.5M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Novel HCV vaccine antigens targeting conserved neutralizing epitopesU19AI123861 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2016 to 2020
$4.6M
Rational design and B cell responses of HIV epitope vaccinesR01AI129698 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2017 to 2021
$3.2M
Structure-based immunogen design for hepatitis C virusR21AI118686 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2015 to 2016
$525k
NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI129698NIAID NIH HHS R21 AI118686NIAID NIH HHS U19 AI123861NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) have provided valuable insights into the humoral immune response to HIV-1. While rationally designed epitope scaffolds and well-folded gp140 trimers have been proposed as vaccine antigens, a comparative understanding of their antibody responses has not yet been established. In this study, we probed antibody responses to the N332 supersite and the membrane-proximal external region (MPER) in the context of heterologous protein scaffolds and native-like gp140 trimers. Ferritin nanoparticles and fragment crystallizable (Fc) regions were utilized as multivalent carriers to display scaffold antigens with grafted N332 and MPER epitopes, respectively. Trimeric scaffolds were also identified to stabilize the MPER-containing BG505 gp140.681 trimer in a native-like conformation. Following structural and antigenic evaluation, a subset of scaffold and trimer antigens was selected for immunization in BALB/c mice. Serum binding revealed distinct patterns of antibody responses to these two bNAb targets presented in different structural contexts. For example, the N332 nanoparticles elicited glycan epitope-specific antibody responses that could also recognize the native trimer, while a scaffolded BG505 gp140.681 trimer generated a stronger and more rapid antibody response to the trimer apex than its parent gp140.664 trimer. Furthermore, next-generation sequencing (NGS) of mouse splenic B cells revealed expansion of antibody lineages with long heavy-chain complementarity-determining region 3 (HCDR3) loops upon activation by MPER scaffolds, in contrast to the steady repertoires primed by N332 nanoparticles and a soluble gp140.664 trimer. These findings will facilitate the future development of a coherent vaccination strategy that combines both epitope-focused and trimer-based approaches.

Indexed as

AnimalsAntibodies, NeutralizingAntibody Formationenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesMiceMice, Inbred BALB CAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1HIV Antibodies

Identifiers

PMID28246356
PMCPMC5347340
OpenAlexW2591839907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.